K. Jung et al., SOLUBLE CD44 MOLECULES IN SERUM OF PATIENTS WITH PROSTATE-CANCER AND BENIGN PROSTATIC HYPERPLASIA, European journal of cancer, 32A(4), 1996, pp. 627-630
Recent studies suggest that expression off CD44 splice variants are of
prognostic significance for a variety of neoplasias. It was the aim o
f this study to investigate whether any correlation exists between the
concentration of soluble CD44 molecules in serum (CD44 standard form
and CD44 splice variants v5 and v6) and the prostate cancer stage. Ser
um levels of these soluble CD44 isoforms were measured by ELISA tests
specific for these proteins in controls (n = 30), patients with benign
prostatic hyperplasia (BPH; n = 30), with prostate cancer without met
astasis (T1,2,3pN0M0; n = 30) and with locally advanced prostate cance
r and/or metastatic disease (T3,4pN1,2M1; n = 19). sCD44std and sCD44v
6 concentrations were not significantly different among the four group
s studied, with few patients' levels outside the central 95% reference
intervals. The mean sCD44v5 concentrations of both prostate cancer an
d BPH patients were significantly lower than those of the controls. Th
ere was no significant difference between the soluble CD44 concentrati
ons of the two groups of prostate cancer patients studied. In contrast
to results observed in other carcinomas, the determination of soluble
CD44 proteins in serum is not suitable for providing additional progn
ostic information on patients with prostate cancer. (C) 1996 Elsevier
Science Ltd